ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy
Amar Trivedi1, Bradley P Knight1
1Division of Cardiology, Department of Medicine, Northwestern University, Chicago, IL, USA.
Arrhythmia & Electrophysiology Review
|January 25, 2017
Summary
Hypertrophic cardiomyopathy (HCM) increases sudden cardiac death (SCD) risk. This review covers SCD prevention in HCM patients, focusing on implantable cardioverter-defibrillator (ICD) therapy and risk stratification.
Area of Science:
- Cardiology
- Genetics
- Electrophysiology
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart condition.
- HCM significantly elevates the risk of sudden cardiac death (SCD).
- Ventricular arrhythmias are a key mechanism for SCD in HCM.
Purpose of the Study:
- To review factors influencing SCD prevention in HCM patients.
- To discuss the role of implantable cardioverter-defibrillators (ICDs) in primary SCD prevention.
- To examine current and emerging SCD predictors and risk stratification guidelines.
Main Methods:
- Review of epidemiological data on SCD in HCM.
- Analysis of structural and genetic underpinnings of arrhythmias.
- Evaluation of North American and European risk stratification guidelines.
- Discussion of ICD implantation, programming, and complications.
- Review of data on fully subcutaneous ICDs.
Main Results:
- SCD risk stratification in HCM is complex.
- ICD therapy is crucial for primary prevention in high-risk individuals.
- Emerging predictors and updated guidelines aid risk assessment.
- Subcutaneous ICDs offer an alternative implantation option.
Conclusions:
- Effective SCD prevention in HCM requires understanding risk factors and applying guideline-based strategies.
- ICD therapy, including newer subcutaneous options, plays a vital role.
- Ongoing research into predictors and therapies is essential for improving outcomes.
Keywords:
Hypertrophic cardiomyopathyimplantable cardioverter defibrillatorsubcutaneous implantable cardioverter-defibrillatorsudden cardiac deathMore Related Videos
05:06Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes
Published on: May 5, 2020
14.6K
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
15.5K
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
593
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593
01:29Cardiomyopathy V: Interprofessional Care
564
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
564
01:30Cardiomyopathy II: Dilated Cardiomyopathy
689
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
689
01:14Myocarditis III: Medical Management
282
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
282
01:22Heart Failure VI: Adjunct Therapies
491
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
491
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
699
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
699